Fig. 1From: Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III TrialSchematic representation of MATAO study design, covering the maximum time schedule per patient depending on the differences in in histopathological grading. ER   Estrogen Receptor, PARPi   Poly(ADP-Ribose)-Polymerase 1 inhibitorBack to article page